dismissed Eli Lillys lawsuit against Willow Health, a telehealth company compounding tirzepatide
Medicaid programs in North Carolina, South Carolina, Michigan, New Hampshire, and California have announced plans to eliminate or narrow access to GLP-1 weight-loss treatment in some cases limiting it only to people who are morbidly obese. The reversal reflects tightening budgets, slowing revenue growth, and rising spending demands
Finding the Right Fit for You The choice between these medications depends on several personal factors, your medical history, weight management goals, how well you tolerate different treatments, and what fits best with your lifestyle
The study also shows that, across the obesity-related outcomes included in the study, researchers observed no reduction in medical events over the first two years of therapy
Koniver told me that he has taken it